Uprêvma Health

Uprêvma Health is a clinical-stage biotechnology company focused on developing small molecule therapies for lysosomal storage disorders and neurodegenerative diseases. The company's lead candidate, UPV-101, is a potent, brain-penetrant activator of the enzyme glucocerebrosidase (GBA1). This approach targets the underlying genetic cause of Gaucher disease and addresses GBA1 dysfunction, which is the most common genetic risk factor for Parkinson's disease. Uprêvma is leveraging its deep expertise in rare diseases to advance a pipeline of disease-modifying treatments for patients with high unmet medical needs. The company maintains a close relationship with clinical research centers to accelerate the translation of its scientific discoveries into therapeutic options.